Marc R. Theoret

10.7k total citations · 4 hit papers
139 papers, 6.8k citations indexed

About

Marc R. Theoret is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Marc R. Theoret has authored 139 papers receiving a total of 6.8k indexed citations (citations by other indexed papers that have themselves been cited), including 84 papers in Oncology, 36 papers in Pulmonary and Respiratory Medicine and 27 papers in Immunology. Recurrent topics in Marc R. Theoret's work include Cancer Immunotherapy and Biomarkers (39 papers), CAR-T cell therapy research (30 papers) and Immunotherapy and Immune Responses (22 papers). Marc R. Theoret is often cited by papers focused on Cancer Immunotherapy and Biomarkers (39 papers), CAR-T cell therapy research (30 papers) and Immunotherapy and Immune Responses (22 papers). Marc R. Theoret collaborates with scholars based in United States, United Kingdom and Netherlands. Marc R. Theoret's co-authors include Richard Pazdur, Nicholas P. Restifo, Steven A. Rosenberg, Zhiya Yu, Julia A. Beaver, Kirsten B. Goldberg, Dhanalakshmi Chinnasamy, Rajeev Shrimali, Deborah R. Surman and Rajeshwari Sridhara and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Clinical Investigation.

In The Last Decade

Marc R. Theoret

127 papers receiving 6.7k citations

Hit Papers

Tumor Regression and Autoimmunity after Reversal of a Fun... 2003 2026 2010 2018 2003 2010 2021 2021 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Tumor Regression and Autoimmunity after Reversal of a Functionally Tolerant State of Self-reactive CD8+ T Cells
    2003 751 citations Marc R. Theoret, Steven E. Finkelstein et al. profile →
  2. Antiangiogenic Agents Can Increase Lymphocyte Infiltration into Tumor and Enhance the Effectiveness of Adoptive Immunotherapy of Cancer
    2010 518 citations Rajeev Shrimali, Zhiya Yu et al. profile →
  3. FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden–High Solid Tumors
    2021 330 citations Leigh Marcus, Lola A. Fashoyin‐Aje et al. Clinical Cancer Research profile →
  4. The Drug-Dosing Conundrum in Oncology — When Less Is More
    2021 180 citations Mirat Shah, Atiqur Rahman et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Marc R. Theoret United States 42 4.5k 2.8k 1.4k 1.2k 824 139 6.8k
Jacob Schachter Israel 47 6.5k 1.4× 3.0k 1.1× 3.0k 2.2× 857 0.7× 748 0.9× 189 8.4k
Ravi A. Madan United States 43 4.3k 0.9× 3.2k 1.2× 1.5k 1.1× 2.2k 1.9× 650 0.8× 286 6.7k
Luciana Molinero United States 37 6.6k 1.5× 3.4k 1.2× 1.6k 1.2× 2.2k 1.9× 2.1k 2.6× 102 9.2k
Evan J. Lipson United States 41 5.9k 1.3× 2.2k 0.8× 1.4k 1.0× 1.6k 1.4× 642 0.8× 126 7.7k
Amreen Husain United States 32 4.7k 1.0× 1.4k 0.5× 1.5k 1.1× 1.7k 1.4× 1.4k 1.7× 74 8.2k
Raanan Berger Israel 34 4.2k 0.9× 1.6k 0.6× 2.2k 1.6× 1.9k 1.7× 1.2k 1.4× 160 7.2k
Roberto Salgado Belgium 34 6.5k 1.4× 2.9k 1.1× 1.7k 1.3× 1.7k 1.5× 2.6k 3.2× 147 8.7k
Stéphane Champiat France 32 5.4k 1.2× 1.9k 0.7× 883 0.6× 1.9k 1.7× 493 0.6× 130 7.2k
Paola Queirolo Italy 44 5.3k 1.2× 2.5k 0.9× 3.0k 2.2× 951 0.8× 662 0.8× 233 7.3k
Pier Francesco Ferrucci Italy 37 3.7k 0.8× 1.7k 0.6× 2.9k 2.1× 857 0.7× 409 0.5× 141 6.2k

Countries citing papers authored by Marc R. Theoret

Since Specialization
Citations

This map shows the geographic impact of Marc R. Theoret's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marc R. Theoret with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marc R. Theoret more than expected).

Fields of papers citing papers by Marc R. Theoret

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marc R. Theoret. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marc R. Theoret. The network helps show where Marc R. Theoret may publish in the future.

Co-authorship network of co-authors of Marc R. Theoret

This figure shows the co-authorship network connecting the top 25 collaborators of Marc R. Theoret. A scholar is included among the top collaborators of Marc R. Theoret based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marc R. Theoret. Marc R. Theoret is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Woods, Ashley, Dianne Pulte, Jonathon Vallejo, et al.. (2025). FDA Approval Summary: Ivosidenib for Treatment of Adult Patients with Relapsed/Refractory Myelodysplastic Syndrome with an IDH1 Mutation. Clinical Cancer Research. 31(17). 3613–3617. 1 indexed citations
2.
Rabik, Cara A., Shu Wang, Donna Przepiorka, et al.. (2025). FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy. Clinical Cancer Research. 31(20). 4230–4238.
3.
Shah, Mirat, Ting-Yu Chen, Gwynn Ison, et al.. (2025). Overall Survival and the Evolving Benefit-Risk Assessment for Poly (ADP-ribose) Polymerase Inhibitors in Advanced Ovarian Cancer. Journal of Clinical Oncology. 43(19). 2218–2227. 1 indexed citations
4.
Le, Robert Q., Kamar Godder, Moran Choe, et al.. (2025). FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy. Clinical Cancer Research. 31(17). 3607–3612.
5.
Bross, Peter, Karin M. Knudson, Million A. Tegenge, et al.. (2025). FDA Approval Summary: Lifileucel for Unresectable or Metastatic Melanoma Previously Treated with an Anti–PD-1–Based Immunotherapy. Clinical Cancer Research. 31(19). 4004–4009. 1 indexed citations
6.
Chow, Edwin C.Y., Alexei Ionan, Shwu‐Luan Lee, et al.. (2024). FDA Approval Summary: Asciminib for Ph+ CML in Chronic Phase Treated with Two or More Tyrosine Kinase Inhibitors and for the T315I Mutation. Clinical Cancer Research. 30(19). 4266–4271. 2 indexed citations
7.
Cortes, Jörge E., Elisabetta Abruzzese, Elyce Cardonick, et al.. (2024). Perspectives on Drug Development for the Treatment of Chronic Myeloid Leukemia in Pregnant Patients and Patients Who Are Breastfeeding. Clinical Cancer Research. 30(17). 3658–3666. 2 indexed citations
8.
Woods, Ashley, Kelly J. Norsworthy, Jonathon Vallejo, et al.. (2023). FDA Approval Summary: Ivosidenib in Combination with Azacitidine for Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation. Clinical Cancer Research. 30(7). 1226–1231. 16 indexed citations
9.
Pinato, David J., Xiaoxue Li, Pallavi S. Mishra‐Kalyani, et al.. (2023). Association between antibiotics and adverse oncological outcomes in patients receiving targeted or immune-based therapy for hepatocellular carcinoma. JHEP Reports. 5(6). 100747–100747. 33 indexed citations
10.
Baines, Andrea, Bindu Kanapuru, Guoxiang Shen, et al.. (2022). FDA Approval Summary: Belantamab Mafodotin for Patients with Relapsed or Refractory Multiple Myeloma. Clinical Cancer Research. 28(21). 4629–4633. 34 indexed citations
11.
Zirkelbach, Jeanne Fourie, Mirat Shah, Jonathon Vallejo, et al.. (2022). Improving Dose-Optimization Processes Used in Oncology Drug Development to Minimize Toxicity and Maximize Benefit to Patients. Journal of Clinical Oncology. 40(30). 3489–3500. 97 indexed citations
12.
Marcus, Leigh, M. Naomi Horiba, Martha Donoghue, et al.. (2022). FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement. Clinical Cancer Research. 29(5). 838–842. 33 indexed citations
13.
Saung, May Tun, Lorraine Pelosof, Sandra J. Casak, et al.. (2021). FDA Approval Summary: Nivolumab Plus Ipilimumab for the Treatment of Patients with Hepatocellular Carcinoma Previously Treated with Sorafenib. The Oncologist. 26(9). 797–806. 77 indexed citations
14.
Schneider, Julie A., Yutao Gong, Kirsten B. Goldberg, et al.. (2021). The FDA Oncology Center of Excellence Scientific Collaborative: Charting a Course for Applied Regulatory Science Research in Oncology. Clinical Cancer Research. 27(19). 5161–5167. 1 indexed citations
15.
Mathieu, Luckson, Sujay Shah, Lee H. Pai-Scherf, et al.. (2021). FDA Approval Summary: Atezolizumab and Durvalumab in Combination with Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung Cancer. The Oncologist. 26(5). 433–438. 102 indexed citations
16.
17.
O’Leary, Maura, Xiaobin Lü, Ying Huang, et al.. (2018). FDA Approval Summary: Tisagenlecleucel for Treatment of Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia. Clinical Cancer Research. 25(4). 1142–1146. 221 indexed citations
18.
Davis, Jeremy L., Marc R. Theoret, Zhili Zheng, et al.. (2010). Development of Human Anti-Murine T-Cell Receptor Antibodies in Both Responding and Nonresponding Patients Enrolled in TCR Gene Therapy Trials. Clinical Cancer Research. 16(23). 5852–5861. 94 indexed citations
19.
Chinnasamy, Dhanalakshmi, Zhiya Yu, Marc R. Theoret, et al.. (2010). Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. Journal of Clinical Investigation. 120(11). 3953–3968. 205 indexed citations
20.
Klebanoff, Christopher A., Steven E. Finkelstein, Deborah R. Surman, et al.. (2004). IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8 + T Cells. Proceedings of the National Academy of Sciences. 101(7). 1969–1974. 481 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jacob Schachter Breakdown of academic impact, for papers by Ravi A. Madan Breakdown of academic impact, for papers by Luciana Molinero Breakdown of academic impact, for papers by Evan J. Lipson Breakdown of academic impact, for papers by Amreen Husain Breakdown of academic impact, for papers by Raanan Berger Breakdown of academic impact, for papers by Roberto Salgado Breakdown of academic impact, for papers by Stéphane Champiat Breakdown of academic impact, for papers by Paola Queirolo Breakdown of academic impact, for papers by Pier Francesco Ferrucci
Rankless by CCL
2026